Additional Health and Economic Impact of the Bivalent Versus the Quadrivalent HPV Vaccine in Taiwan: Results of a Prevalence-based Model
This study uses a prevalence-based model (by using efficacy data from each vaccine's
respective trials and published cost data for Taiwan) which estimates the differences in
lesions, genital warts, cervical cancer and costs from a healthcare payer's perspective
prevented between HPV-1 and HPV-2 vaccines during one year (when all women are vaccinated).
It also analyses costs from a societal perspective.
Annual number of lesions prevented by each vaccine
Over a one-year period
GSK Clinical Trials
Taiwan: Food and Drug Administration, Department of Health